open access

Vol 72, No 1 (2021)
Original paper
Published online: 2020-08-27
Submitted: 2020-03-05
Accepted: 2020-05-30
Get Citation

miR-597-3p inhibits invasion and migration of thyroid carcinoma SW579 cells by targeting RAB23

Hu-Ling Wen, Zheng-Min Xu, Shi-Yu Lin, Dan Wen, Jian Ping Xie
DOI: 10.5603/EP.a2020.0041
·
Pubmed: 32856288
·
Endokrynologia Polska 2021;72(1):22-28.

open access

Vol 72, No 1 (2021)
Original Paper
Published online: 2020-08-27
Submitted: 2020-03-05
Accepted: 2020-05-30

Abstract

Introduction: Nowadays, it is indicated that miRNA was anomaly expressed in tumour. Previous studies have shown that miRNAs can regulate the proliferation, invasion, and migration of cancer cell-related processes. Meanwhile, current investigations show that RAB23 also plays an important role in cancer cell-related processes. But the potential mechanism remains unclear.

Material and methods: SW579 cells were selected and transfected with miR-597-3p mimics. Then the expression of miR-597-3p and RAB23 were measured by quantitative real-time polymerase chain reaction (PCR) and western blotting, respectively. Subsequently, the abilities of proliferation, invasion, and migration of SW579 cells were researched. For further study, the Luciferase reporter assay proved that miR-597-3p could target the expression of RAB23, and the proteins of invasion and migration were also measured to clear the mechanism.

Results: After being transfected with miR-597-3p mimics, the expression of miR-597-3p was remarkably increased and RAB23 was significantly decreased. The abilities of proliferation, invasion, and migration also decreased significantly. The miRTarase Database predicated and Luciferase reporter assay proved that RAB23 was the target gene of miR-597-3p. The expression of matrix metalloproteinase (MMP)-2, MMP-9, and N-cadherin was down-regulated, and the expression of E-cadherin was up-regulated.

Conclusion: miR-597-3p could reduce the proliferation, invasion and migration abilities of SW579 cells, which may be related to the targeted inhibition of RAB23 expression and down-regulation of the expression levels of MMP-2, MMP-9 and N-cadherin proteins of SW579 cells.

Abstract

Introduction: Nowadays, it is indicated that miRNA was anomaly expressed in tumour. Previous studies have shown that miRNAs can regulate the proliferation, invasion, and migration of cancer cell-related processes. Meanwhile, current investigations show that RAB23 also plays an important role in cancer cell-related processes. But the potential mechanism remains unclear.

Material and methods: SW579 cells were selected and transfected with miR-597-3p mimics. Then the expression of miR-597-3p and RAB23 were measured by quantitative real-time polymerase chain reaction (PCR) and western blotting, respectively. Subsequently, the abilities of proliferation, invasion, and migration of SW579 cells were researched. For further study, the Luciferase reporter assay proved that miR-597-3p could target the expression of RAB23, and the proteins of invasion and migration were also measured to clear the mechanism.

Results: After being transfected with miR-597-3p mimics, the expression of miR-597-3p was remarkably increased and RAB23 was significantly decreased. The abilities of proliferation, invasion, and migration also decreased significantly. The miRTarase Database predicated and Luciferase reporter assay proved that RAB23 was the target gene of miR-597-3p. The expression of matrix metalloproteinase (MMP)-2, MMP-9, and N-cadherin was down-regulated, and the expression of E-cadherin was up-regulated.

Conclusion: miR-597-3p could reduce the proliferation, invasion and migration abilities of SW579 cells, which may be related to the targeted inhibition of RAB23 expression and down-regulation of the expression levels of MMP-2, MMP-9 and N-cadherin proteins of SW579 cells.

Get Citation

Keywords

miR-597-3p; invasion; migration; thyroid carcinoma; SW579 cells

About this article
Title

miR-597-3p inhibits invasion and migration of thyroid carcinoma SW579 cells by targeting RAB23

Journal

Endokrynologia Polska

Issue

Vol 72, No 1 (2021)

Article type

Original paper

Pages

22-28

Published online

2020-08-27

DOI

10.5603/EP.a2020.0041

Pubmed

32856288

Bibliographic record

Endokrynologia Polska 2021;72(1):22-28.

Keywords

miR-597-3p
invasion
migration
thyroid carcinoma
SW579 cells

Authors

Hu-Ling Wen
Zheng-Min Xu
Shi-Yu Lin
Dan Wen
Jian Ping Xie

References (31)
  1. Liu K, Huang W, Yan DQ, et al. Overexpression of long intergenic noncoding RNA LINC00312 inhibits the invasion and migration of thyroid cancer cells by down-regulating microRNA-197-3p. Biosci Rep. 2017; 37(4).
  2. Pishkari S, Paryan M, Hashemi M, et al. The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies. J Endocrinol Invest. 2018; 41(3): 269–283.
  3. Sanabria A, Kowalski LP, Shah JP, et al. Growing incidence of thyroid carcinoma in recent years: Factors underlying overdiagnosis. Head Neck. 2018; 40(4): 855–866.
  4. Lin Y, Ma Q, Li L, et al. The CXCL12-CXCR4 axis promotes migration, invasiveness, and EMT in human papillary thyroid carcinoma B-CPAP cells via NF-κB signaling. Biochem Cell Biol. 2018; 96(5): 619–626.
  5. Au JK, Alonso J, Kuan EC, et al. Primary Squamous Cell Carcinoma of the Thyroid: A Population-Based Analysis. Otolaryngol Head Neck Surg. 2017; 157(1): 25–29.
  6. Natalia MA, Alejandro GT, Virginia TVJ, et al. MARK1 is a Novel Target for miR-125a-5p: Implications for Cell Migration in Cervical Tumor Cells. Microrna. 2018; 7(1): 54–61.
  7. Li D, Zhang Y, Zhang He, et al. CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2018; 37(1): 46.
  8. Zheng S, Zhang X, Wang X, et al. Downregulation of miR-138 predicts poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Biomark. 2017; 20(1): 49–54.
  9. Xue KC, Hu DD, Zhao L, et al. MiR-577 inhibits papillary thyroid carcinoma cell proliferation, migration and invasion by targeting SphK2. Eur Rev Med Pharmacol Sci. 2017; 21(17): 3794–3800.
  10. Wang WW, Chen B, Lei CB, et al. miR-582-5p inhibits invasion and migration of salivary adenoid cystic carcinoma cells by targeting FOXC1. Jpn J Clin Oncol. 2017; 47(8): 690–698.
  11. Li Z, Hu Y, Zeng Q, et al. Circular RNA MYLK promotes hepatocellular carcinoma progression by increasing Rab23 expression by sponging miR-362-3p. Cancer Cell Int. 2019; 19: 211.
  12. Hor CHH, Tang BL, Goh ELK. Rab23 and developmental disorders. Rev Neurosci. 2018; 29(8): 849–860.
  13. Wang Y, Qin H. miR-338-3p targets and suppresses tumorigenicity of prostate cancer cells. Am J Cancer Res. 2018; 8(12): 2564–2574.
  14. Zhang W, Yu F, Wang Yu, et al. Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway. Oncol Lett. 2018; 15(4): 5155–5160.
  15. Wang CJ, Yang D, Luo YW. Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition. Exp Ther Med. 2015; 10(2): 603–607.
  16. Kalra R, Pawar R, Hasija S, et al. Frontal bone metastasis from an occult follicular thyroid carcinoma: Diagnosed by FNAC. J Cytol. 2017; 34(1): 59–61.
  17. Yuan Q, Liu Y, Fan Y, et al. LncRNA HOTTIP promotes papillary thyroid carcinoma cell proliferation, invasion and migration by regulating miR-637. Int J Biochem Cell Biol. 2018; 98: 1–9.
  18. van Beijnum JR, Giovannetti E, Poel D, et al. miRNAs: micro-managers of anticancer combination therapies. Angiogenesis. 2017; 20(2): 269–285.
  19. Dong F, Xu T, Shen Y, et al. Dysregulation of miRNAs in bladder cancer: altered expression with aberrant biogenesis procedure. Oncotarget. 2017; 8(16): 27547–27568.
  20. Adhami M, Haghdoost AA, Sadeghi B, et al. Candidate miRNAs in human breast cancer biomarkers: a systematic review. Breast Cancer. 2018; 25(2): 198–205.
  21. Wang Y, Qin H. miR-338-3p targets and suppresses tumorigenicity of prostate cancer cells. Am J Cancer Res. 2018; 8(12): 2564–2574.
  22. Colden M, Dar AA, Saini S, et al. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. Cell Death Dis. 2017; 8(1): e2572.
  23. Zang C, Sun J, Liu W, et al. miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma. Hum Cell. 2019; 32(4): 428–436.
  24. Meng D, Li Z, Ma X, et al. MicroRNA-1280 modulates cell growth and invasion of thyroid carcinoma through targeting estrogen receptor α. Cell Mol Biol (Noisy-le-grand). Cell Mol Biol (Noisy-le-grand). 2016; 62(3): 1–6.
  25. Wang Y, Wu N, Pang Bo, et al. TRIB1 promotes colorectal cancer cell migration and invasion through activation MMP-2 via FAK/Src and ERK pathways. Oncotarget. 2017; 8(29): 47931–47942.
  26. Farabegoli F, Govoni M, Spisni E, et al. EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion. Biosci Rep. 2017; 37(3).
  27. Song Ye, Zheng S, Wang J, et al. Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma. Oncotarget. 2017; 8(26): 41947–41962.
  28. Feng H, Lu JJ, Wang Y, et al. Osthole inhibited TGF β-induced epithelial-mesenchymal transition (EMT) by suppressing NF-κB mediated Snail activation in lung cancer A549 cells. Cell Adh Migr. 2017; 11(5-6): 464–475.
  29. Zhang XY, Mu JH, Liu LY, et al. Upregulation of miR-802 suppresses gastric cancer oncogenicity via targeting RAB23 expression. Eur Rev Med Pharmacol Sci. 2017; 21(18): 4071–4078.
  30. Cheng L, Yang F, Zhou B, et al. RAB23, regulated by miR-92b, promotes the progression of esophageal squamous cell carcinoma. Gene. 2016; 595(1): 31–38.
  31. Xue H, Tian GY. MiR-429 regulates the metastasis and EMT of HCC cells through targeting RAB23. Arch Biochem Biophys. 2018; 637: 48–55.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl